Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | PRKDC | P78527 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14439519 | 0.94 | ALDH1A1 (0.66) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL18953087 | 0.90 | ALDH1A1 (0.60) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL18039273 | 0.89 | ALDH1A1 (0.49) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL27118585 | 0.89 | ALDH1A1 (0.66) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL4185655 | 0.89 | ALDH1A1 (0.66) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL28629055 | 0.86 | ALDH1A1 (0.77) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL18554131 | 0.85 | ALDH1A1 (0.57) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL2553602 | 0.85 | ALDH1A1 (0.68) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL2557444 | 0.84 | ALDH1A1 (0.66) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL30944553 | 0.84 | ALDH1A1 (0.44) | ALDH1A1MAPTCYP3A4KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115028903-B | Hydrogel and preparation method and application thereof | 广州创赛生物医用材料有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115028903-A | Hydrogel and preparation method and application thereof | 广州创赛生物医用材料有限公司 | 2022-09-09 | — | — | CN | claimed |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2026-03-24 | — | — | US | disclosed |
| WO-2025224196-A1 | COMPOUNDS | KING'S COLLEGE LONDON (GB) | 2025-10-30 | — | — | WO | disclosed |
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | PHEON THERAPEUTICS LTD (GB) | 2025-01-09 | — | — | US | disclosed |
| WO-2024127333-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024127332-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| CN-116870243-B | Hydrogel with hemostatic and anti-inflammatory effects and preparation method and application thereof | 广州创赛生物医用材料有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2007039752-A1 | ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C] [1, 4] BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE | SPIROGEN LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039752-A1 | ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C] [1, 4] BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE | SPIROGEN LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
| US-7169814-B2 | Guanidinium transport reagents and conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060264622-A1 | Synthesis of protected pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1664049-A1 | SYNTHESIS OF PROTECTED PYRROLOBENZODIAZEPINES | Spirogen Limited (GB) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023814-A1 | SYNTHESIS OF PROTECTED PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2005-03-17 | — | — | WO | disclosed |
| US-20040152629-A1 | For use as anticancer compounds and prodrugs | CANCER RESEARCH VENTURES LIMITED (GB) | 2004-08-05 | — | — | US | disclosed |
| EP-1351912-A2 | SUBSTITUTED STILBENES, THEIR REACTIONS AND ANTICANCER ACTIVITY | Cancer Research Ventures Limited (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002050007-A2 | SUBSTITUTED STILBENES, THEIR REACTIONS AND ANTICANCER ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152629-A1 | For use as anticancer compounds and prodrugs | QPCT, PAM, AURKB | ALDH1A1 1417/4885MAPT 3571/4885CYP3A4 115/4885 |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, MTNR1B, MTNR1A | ALDH1A1 1463/4885MAPT 3224/4885CYP3A4 2445/4885 |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | CCND2, BRD2, CCND3 | ALDH1A1 3182/4885MAPT 4580/4885CYP3A4 1490/4885 |
| US-20060264622-A1 | Synthesis of protected pyrrolobenzodiazepines | SBDS, DRD2, GRIN2D | ALDH1A1 2133/4885MAPT 852/4885CYP3A4 281/4885 |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | MKI67, CCND2, CCND1 | ALDH1A1 443/4885MAPT 2106/4885CYP3A4 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.